| Paul K Ritchie, MD | |
|
1184 E 80 N, American Fork, UT 84003-2906 | |
| (801) 763-3885 | |
| (801) 763-3887 |
| Full Name | Paul K Ritchie |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 26 Years |
| Location | 1184 E 80 N, American Fork, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720021678 | NPI | - | NPPES |
| 86345 | Other | UT | DMBA |
| 870281028000 | Medicaid | UT | |
| 107029565101 | Other | UT | IHC |
| P00202105 | Other | PALMETTO GBA | |
| 09-00764 | Other | UT | UNITED HEALTHCARE |
| 222391 | Other | UT | ALTIUS |
| 78935 | Other | UT | PEHP |
| 870281028PKR | Other | UT | EMIA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 5694941-1205 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Utah Clinic Pc | 7517868508 | 391 |
News Archive
A new book based on 27 years of research work emphasises the importance of families who use donor insemination being open and honest with their children about their origins.
The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine.
The National Comprehensive Cancer Network Oncology Research Program is collaborating with Pfizer Independent Grants for Learning & Change (IGLC) to establish a peer-reviewed grant program to elicit proposals focused on health care provider performance and/or health care quality improvement and education projects.
A team of scientists from Portugal has recently estimated the rate of mutation in two circulating variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using experimental evolution methods. Their findings reveal that in a condition with no immune surveillance, SARS-CoV-2 can potentially undergo evolution during the first stages of infection. The study is currently available on the bioRxiv* preprint server.
Three times as many women with advanced lung cancer were alive and had no progression of their cancer 12 months after taking the drug erlotinib (also known as Tarceva) compared to those who did not receive the drug according to new data being presented at the ASCO1 conference today (Monday).
› Verified 8 days ago
| Entity Name | Central Utah Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093764805 PECOS PAC ID: 7517868508 Enrollment ID: O20040113000805 |
News Archive
A new book based on 27 years of research work emphasises the importance of families who use donor insemination being open and honest with their children about their origins.
The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine.
The National Comprehensive Cancer Network Oncology Research Program is collaborating with Pfizer Independent Grants for Learning & Change (IGLC) to establish a peer-reviewed grant program to elicit proposals focused on health care provider performance and/or health care quality improvement and education projects.
A team of scientists from Portugal has recently estimated the rate of mutation in two circulating variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using experimental evolution methods. Their findings reveal that in a condition with no immune surveillance, SARS-CoV-2 can potentially undergo evolution during the first stages of infection. The study is currently available on the bioRxiv* preprint server.
Three times as many women with advanced lung cancer were alive and had no progression of their cancer 12 months after taking the drug erlotinib (also known as Tarceva) compared to those who did not receive the drug according to new data being presented at the ASCO1 conference today (Monday).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul K Ritchie, MD 1055 N 500 W, Credentialing Department, Provo, UT 84604-3305 Ph: (801) 354-8225 | Paul K Ritchie, MD 1184 E 80 N, American Fork, UT 84003-2906 Ph: (801) 763-3885 |
News Archive
A new book based on 27 years of research work emphasises the importance of families who use donor insemination being open and honest with their children about their origins.
The targeted drug nivolumab significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, according to results to be presented at the 2015 European Cancer Congress today (Saturday) and published simultaneously in the New England Journal of Medicine.
The National Comprehensive Cancer Network Oncology Research Program is collaborating with Pfizer Independent Grants for Learning & Change (IGLC) to establish a peer-reviewed grant program to elicit proposals focused on health care provider performance and/or health care quality improvement and education projects.
A team of scientists from Portugal has recently estimated the rate of mutation in two circulating variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using experimental evolution methods. Their findings reveal that in a condition with no immune surveillance, SARS-CoV-2 can potentially undergo evolution during the first stages of infection. The study is currently available on the bioRxiv* preprint server.
Three times as many women with advanced lung cancer were alive and had no progression of their cancer 12 months after taking the drug erlotinib (also known as Tarceva) compared to those who did not receive the drug according to new data being presented at the ASCO1 conference today (Monday).
› Verified 8 days ago
Alan M Banks, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 1184 E 80 N, American Fork, UT 84003 Phone: 801-763-3885 Fax: 801-763-3887 | |
John T Wells, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1184 E 80 N, American Fork, UT 84003 Phone: 801-763-3885 Fax: 801-763-3887 | |
Gordon H Stock, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1184 E 80 N, American Fork, UT 84003 Phone: 801-763-3885 Fax: 801-763-3887 |